{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:50:36Z","timestamp":1786978236394,"version":"build-2736575974"},"reference-count":69,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4353,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mov Disord."],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1002\/mds.10575","type":"journal-article","created":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T04:00:47Z","timestamp":1065067247000},"page":"S28-S33","source":"Crossref","is-referenced-by-count":91,"special_numbering":"supplement 7","title":["DAT imaging in drug-induced and psychogenic parkinsonism"],"prefix":"10.1002","volume":"18","author":[{"given":"Eduardo","family":"Tolosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1002\/mds.10575-BIB1","first-page":"860","article-title":"Psychogenic parkinsonism: confirmation of diagnosis with \u03b2-CIT SPECT scans","volume":"13","author":"Factor","year":"1998","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","article-title":"The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism","volume":"28","author":"Booij","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1002\/mds.10575-BIB3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.1956.02970030032008","article-title":"Neurotoxic reactions resulting from chlorpromazine administration","volume":"161","author":"Hall","year":"1956","journal-title":"J Am Med Assoc"},{"key":"10.1002\/mds.10575-BIB4","first-page":"125","article-title":"Drug-induced parkinsonism: a growing list","volume":"8","author":"Marti-Mass\u00f3","year":"1993","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB5","first-page":"317","article-title":"Actividad asistencial en una consulta hospitalaria especializada en enfermedad de parkinson y transtornos del movimiento: un estudio prospectivo durante anos","volume":"9","author":"P\u00e9rez-Gilabert","year":"1994","journal-title":"Neurologia (Spain)"},{"key":"10.1002\/mds.10575-BIB6","first-page":"10","article-title":"Parkinsonismo inducido o agravado por f\u00e1rmacos: caracter\u00edsticas cl\u00ednicas y evoluci\u00f3n hist\u00f3rica de los f\u00e1rmacos implicados","volume":"11","author":"Marti-Mass\u00f3","year":"1996","journal-title":"Neurologia (Spain)"},{"key":"10.1002\/mds.10575-BIB7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1212\/WNL.42.10.1901","article-title":"Prevalence of parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities","volume":"42","author":"Morgante","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","article-title":"Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa","volume":"51","author":"Hardie","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.10575-BIB9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","article-title":"A survey of drug-induced extrapyramidal reactions","volume":"175","author":"Ayd","year":"1961","journal-title":"JAMA"},{"key":"10.1002\/mds.10575-BIB10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0140-6736(84)91516-2","article-title":"Drug-induced parkinsonism in the elderly","volume":"2","author":"Stephen","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/mds.10575-BIB11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/archinte.1989.00390110070015","article-title":"Metoclopramide-induced movement disorders","volume":"149","author":"Miller","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1002\/mds.10575-BIB12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0163-8343(92)90069-M","article-title":"Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents","volume":"14","author":"Hansen","year":"1992","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1002\/mds.10575-BIB13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00002018-199716030-00004","article-title":"Drug-induced movement disorders","volume":"3","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1997","journal-title":"Drug Saf"},{"key":"10.1002\/mds.10575-BIB14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.43.3_Part_1.552","article-title":"Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study","volume":"43","author":"Burn","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007611-199005000-00011","article-title":"Neurologic approach to drug-induced movement disorders: a study of 125 patients","volume":"8","author":"Miller","year":"1990","journal-title":"South Med J"},{"key":"10.1002\/mds.10575-BIB16","first-page":"1300","article-title":"Parkinsonism, tardive dyskinesia, akathisia and depression-induced by flunarizine","volume":"1","author":"Chouza","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/mds.10575-BIB17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/WNL.37.5.881","article-title":"Flunarizine and cinnarizine-induced extrapyramidal reactions","volume":"7","author":"Micheli","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB18","first-page":"341","article-title":"The coexistence of parkinsonism-like symptoms and tardive dyskinesia","volume":"19","author":"Richardson","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1002\/mds.10575-BIB19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00002826-198712000-00002","article-title":"Coexistent tardive dyskinesia and parkinsonism","volume":"10","author":"Jankovic","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.10575-BIB20","first-page":"13","article-title":"Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment","volume":"44","author":"Hausner","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/mds.10575-BIB21","volume-title":"Psychiatric aspects of neurologic disease","author":"Marsden","year":"1975"},{"key":"10.1002\/mds.10575-BIB22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(70)90368-5","article-title":"Levodopa in drug-induced extrapyramidal disorders","volume":"2","author":"Fleming","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/mds.10575-BIB23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000102857","article-title":"Prolonged drug-induced Parkinsonism","volume":"35","author":"Klawans","year":"1973","journal-title":"Confin Neurol"},{"key":"10.1002\/mds.10575-BIB24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archpsyc.1989.01810040089017","article-title":"Parkinsonism following neuroleptic withdrawal","volume":"46","author":"Nelli","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/mds.10575-BIB25","first-page":"23","article-title":"Adverse neurologic effects of metoclopramide","volume":"126","author":"Grimes","year":"1982","journal-title":"Can Med Assoc J"},{"key":"10.1002\/mds.10575-BIB26","volume-title":"Movement disorders: neurologic principles and practice","author":"Hubble","year":"1996"},{"key":"10.1002\/mds.10575-BIB27","first-page":"599","volume-title":"Movement disorders: a comprehensive survey","author":"Weiner","year":"1989"},{"key":"10.1002\/mds.10575-BIB28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine: a novel antipsychotic agent","volume":"324","author":"Baldenassarini","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/mds.10575-BIB29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-199651060-00001","article-title":"Adverse effects of antipsychotic agents. Do newer agents offer advantages?","volume":"51","author":"Owens","year":"1996","journal-title":"Drugs"},{"key":"10.1002\/mds.10575-BIB30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1002\/mds.10575-BIB31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002826-199202000-00003","article-title":"Parkinsonism associated with calcium-channel blockers (CCB). A prospective follow-up study","volume":"15","author":"Garc\u00eda-Ru\u00edz","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.10575-BIB32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.55.4.598","article-title":"Movement disorders secondary to adulterated medication","volume":"55","author":"Consentino","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/mds.10575-BIB34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/ajp.143.2.232","article-title":"Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol","volume":"143","author":"Moleman","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1002\/mds.10575-BIB35","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/jnnp.39.9.866","article-title":"Extrapyramidal effects of neuroleptics","volume":"39","author":"Korczyn","year":"1976","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.10575-BIB36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410330516","article-title":"Neuroleptic medications inhibit complex I of the electron transport chain","volume":"33","author":"Burkhardt","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1002\/mds.10575-BIB37","first-page":"158","article-title":"Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implications for parkinsonism","volume":"45","author":"Veitch","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1002\/mds.10575-BIB38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.870040203","article-title":"HLA antigens in drug-induced parkinsonism","volume":"4","author":"Metzer","year":"1989","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002826-199106000-00013","article-title":"Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?","volume":"14","author":"Melamed","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.10575-BIB40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00002826-199204000-00010","article-title":"Cinnarizine-induced parkinsonism in primates","volume":"15","author":"Garc\u00eda-Ru\u00edz","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.10575-BIB41","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0006-2952(95)02057-8","article-title":"Possible pharmacokinetics and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine","volume":"50","author":"Kariya","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/mds.10575-BIB42","first-page":"515","article-title":"Tetrabenazine, an amine depleting agent, also blocks dopamine receptors in rat brain","volume":"225","author":"Reches","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/mds.10575-BIB43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/WNL.42.2.459","article-title":"Unsuspected, surreptitious drug-induced parkinsonism","volume":"42","author":"Albanese","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archneur.1983.04050050093019","article-title":"Drug-induced parkinsonism and idiopathic Parkinson's disease","volume":"40","author":"Goetz","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.10575-BIB45","first-page":"340","volume-title":"The psychopharmacology and treatment of schizophrenia","author":"Marsden","year":"1986"},{"key":"10.1002\/mds.10575-BIB46","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archneur.1982.00510220042009","article-title":"Reversible drug-induced parkinsonism: clinicopathologic study of two cases","volume":"39","author":"Rajput","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.10575-BIB47","first-page":"7","article-title":"The genetics of Parkinson's disease: a reconsideration","volume":"40","author":"Golbe","year":"1990","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archneur.1982.00510200036006","article-title":"metoclopramide induced parkinsonism: clinical characteristics of ten cases","volume":"39","author":"Indo","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.10575-BIB49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","article-title":"A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism","volume":"12","author":"Negrotti","year":"1997","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1471-4159.1993.tb03174.x","article-title":"Comparison of [3H]WIN 35,428 binding, a marker for dopamine transport, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats","volume":"60","author":"Valchar","year":"1993","journal-title":"J Neurochem"},{"key":"10.1002\/mds.10575-BIB51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0014-2999(84)90403-5","article-title":"Blockade by antidepressants and related compounds with biogenic amines uptake into rat brains synaptosomes: most antidepressants selectively block norepinephrine uptake","volume":"104","author":"Richelson","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/mds.10575-BIB52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-8993(95)00611-S","article-title":"Brain dopamine transporter: gender differences and effect of chronic haloperidol","volume":"692","author":"Rivest","year":"1995","journal-title":"Brain Res"},{"key":"10.1002\/mds.10575-BIB53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1022405621365","article-title":"Neuroleptics and dopamine transporters","volume":"23","author":"Reader","year":"1998","journal-title":"Neurochem Res"},{"key":"10.1002\/mds.10575-BIB54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0920-9964(00)00023-2","article-title":"Dopamine transporter density in young patients with schizophrenia assessed with [123]I FP-CIT SPECT","volume":"47","author":"Lavalaye","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1002\/mds.10575-BIB55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-9964(00)00095-5","article-title":"Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia","volume":"52","author":"Laakso","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1002\/mds.10575-BIB56","first-page":"1970","article-title":"Pseudoneurologic syndromes: recognition and diagnosis","volume":"58","author":"Shaibani","year":"1998","journal-title":"Am Fam Physician"},{"key":"10.1002\/mds.10575-BIB57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/jnnp.59.4.406","article-title":"Psychogenic movement disorders: frequency, clinical profile, and characteristics","volume":"59","author":"Factor","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.10575-BIB58","first-page":"475","volume-title":"Treatment of movement disorders","author":"Ford","year":"1995"},{"key":"10.1002\/mds.10575-BIB59","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1995.00540320078015","article-title":"Psychogenic parkinsonism","volume":"52","author":"Lang","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.10575-BIB60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0317167100003292","article-title":"Psychogenic movement disorders","volume":"30","author":"Miyasaki","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"10.1002\/mds.10575-BIB61","first-page":"431","article-title":"Psychogenic dystonia","volume":"50","author":"Fahn","year":"1998","journal-title":"Adv Neurol"},{"key":"10.1002\/mds.10575-BIB62","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/WNL.39.8.1094","article-title":"Psychogenic tremors","volume":"39","author":"Koller","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mds.870130216","article-title":"Diagnostic and pathophysiological aspects of psychogenic tremor","volume":"13","author":"Deuschl","year":"1998","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB64","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/brain\/124.6.1077","article-title":"Functional neuroanatomical correlates of hysterical sensorimotor loss","volume":"124","author":"Vuilleumier","year":"2001","journal-title":"Brain"},{"key":"10.1002\/mds.10575-BIB65","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(00)02096-1","article-title":"Discrete neurophysiological correlates in prefrontal cortex during hysterical and feigned disorder of movement","volume":"355","author":"Spence","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/mds.10575-BIB66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/mds.870050206","article-title":"Psychogenic dyskinesias in patients with organic movement disorders","volume":"5","author":"Ranawaya","year":"1990","journal-title":"Mov Disord"},{"key":"10.1002\/mds.10575-BIB67","first-page":"431","article-title":"Psychogenic dystonia","volume":"50","author":"Fahn","year":"1998","journal-title":"Adv Neurol"},{"key":"10.1002\/mds.10575-BIB68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1212\/WNL.43.2.349","article-title":"Psychogenic myoclonus","volume":"43","author":"Monday","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/mds.10575-BIB69","first-page":"131","article-title":"Confirming Parkinson's disease with [123I]FP-CIT SPECT","volume":"6","author":"O'Sullivan","year":"1999","journal-title":"Eur J Neurol"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10575","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/mds.10575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T09:16:17Z","timestamp":1625476577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mds.10575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":69,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2003,10]]}},"URL":"https:\/\/doi.org\/10.1002\/mds.10575","relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}